Redeye provides an update following Neola Medical’s Q2 2025 report. The quarterly figures were in line with our expectations. We also highlight that clinical data from the Swedish study in H2 2025 could act as a potential share price trigger. Based on the report, we have made minor adjustments to our estimates, resulting in small changes to our fair value range.
LÄS MER
